|
Post-market: Market edgy on expiry jitters, pharma gains
|
Tuesday, March 23, 2010 |
| 
| March 23, 2010 | 5:30 PM | Market edgy on expiry jitters, pharma gains Market whipsaws with March F&O contracts expiring on day after tomorrow; US Healthcare Reforms Bill sees healthcare scrips trade higher. | | | | | | Major headlines | - Cadila Healthcare hits its 52-week high; the stock surges 4.60%
- ICICI Bank gets full license for Singapore operations; the stock closes 1.05% lower
- Larsen & Toubro secures orders worth Rs1,500 crore; the stock finishes 0.36% down
Post-market summary | Indian indices With the expiry of March F&O contracts round the corner?on Thrusday (March 25, 2010)?stocks fluctuated as investors unwound positions. The passing of the US Healthcare Reform Bill, touted to be historic in nature, yesterday, which could benefit Indian drug makers saw pharmaceutical stocks (BSE Healthcare) open higher and stay higher. Starting off merely 22 points over its yesterday?s close the Sensex was its day?s high (120 up its yesterday?s close) within minutes of trade. However it failed to hold on this early lead on expiry jitters. With little over two hours to the closing it was at its day?s low (54 points lower than its yesterday?s closing), but rebounded towards the end on buying in blue chips like Reliance Industries, Torrent Power and HDFC Bank to post gains of 40 points. The Nifty closed 20 points higher with F&O volumes spiking by over 20% over its yesterday's reading. | | INDEX PERFORMANCE |  | | | | | MARKET INDICATORS |  | | | | | | | | Cadila Healthcare | 840.65 | 4.60 | | | | Idea Cellular | 65.05 | -3.70 | | Shree Renuka Sugar | 72.40 | -3.53 | | | | | | | | | | | | | | | | | | | | | Market sentiment The advance/decline ratio tilled in favour of bears at 0.84. Of the 2,879 stocks traded on the BSE, 1,504 (52.24%) stocks declined, whereas 1,266 (43.97%) stocks advanced. Hundred and nine stocks closed unchanged. Viewing volumes On a day before the expiry of March F&O contracts, F&O volumes spurted to over 1.15 lakh. However, the cash segment did not see much change from average volumes. Steel maker, Ispat Industries was the most actively traded share with over 0.34 crore shares changing hands on the BSE, followed by India?s second largest realty company Unitech (0.34 crore shares), Industrial finance company IFCI (0.28 crore shares), wind turbine major Suzlon Energy (0.27 crore shares) and the Housing Development & infrastructure Ltd (HDIL; 0.23 crore shares). | Sectoral and stock screening Passage of US Healthcare Reforms Bill spiked BSE Health Care (up 1.54%) on news that it would benefit Indian drug companies. BSE Oil & Gas was at second position?up 1.13%. The rest of the sectors were either up or down by less than a percent. On stocks? front, the top three gainers were Areva T&D India (up 10.33%), Lanco Infratech (up 6.84%) and Cadila Healthcare (up 4.60%). The top three losers were NMDC (down 5.47%), Idea Cellular (down 3.70%) and Shree Renuka Sugars (down 4.66%). |  | | | | | | | | Global cues European stocks were trading modestly higher taking cue from an upbeat session on the Wall Street. At the time of writing this report, FTSE 100 (UK) was trading 0.67% higher. Of the major Asian indices, only Shanghai Composite (China) and Nikkei (Japan) ended lower?by 0.70% and 0.47% respectively. SGX Nifty closed 13 points higher. US stock futures opened higher pointing to a higher opening on the Wall Street, with housing in the spotlight ahead of data on prices, existing-home sales and results from builder KB Home. However, the investors would be eagerly waiting for the existing home sales readings for February and FHFA home price index for January. On March 24, 2010, the investors would be eagerly waiting for Durable Orders ex Auto and New Home Sales for February. | | | | Manage your newsletter subscriptions | | | | | | | To know more about our products and services, click here. | | | | | | ?This document has been prepared by Sharekhan Ltd. This Document is subject to changes without prior notice and is intended only for the person or entity to which it is addressed to and may contain confidential and/or privileged material and is not for any type of circulation. Any review, retransmission, or any other use is prohibited. Kindly note that this document does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. SHAREKHAN will not treat recipients as customers by virtue of their receiving this report. The information contained herein is from publicly available data or other sources believed to be reliable. While we would endeavour to update the information herein on reasonable basis, SHAREKHAN, its subsidiaries and associated companies, their directors and employees (?SHAREKHAN and affiliates?) are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent SHAREKHAN and affiliates from doing so. We do not represent that information contained herein is accurate or complete and it should not be relied upon as such. This document is prepared for assistance only and is not intended to be and must not alone betaken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. We do not undertake to advise you as to any change of our views. Affiliates of Sharekhan may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SHAREKHAN and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. SHAREKHAN & affiliates may have used the information set forth herein before publication and may have positions in, may from time to time purchase or sell or may be materially interested in any of the securities mentioned or related securities. SHAREKHAN may from time to time solicit from, or perform investment banking, or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall SHAREKHAN, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. Any comments or statements made herein are those of the analyst and do not necessarily reflect those of SHAREKHAN.? | To unsubscribe write to mailto:myaccount@sharekhan.com
| | |  |
posted by Anonymous @ 11:29 AM  |
|
|
|
|